Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Doctoral Award: Doctoral Foreign Study Award (DFSA)

Direct Payment

$105,000.00

Developing a Molecular Perception-Based Platform for the Early Detection of Ovarian Cancer

FY 2023-24

Summary
Ovarian cancer is the most common gynecological malignancy in Canada, killing over 2 400 women annually. Despite advances in the understanding and treatment of ovarian cancer, survival is poor, especially if diagnosed at a late stage and early-stage detection is rare. This proposal investigates a strategy to improve the diagnosis and screening of ovarian cancer and to identify novel disease biomarkers via a liquid biopsy artificial intelligence-nanosensor prognosis prediction platform. We believe that the differentiation of disease from normal biofluids may be achieved by the detection of a "disease fingerprint" through the acquisition of large data sets of molecular binding interactions to a diverse set of moderately selective sensors, which are used to train machine learning algorithms. We are developing this capability using sensor arrays of chemically modified carbon nanotubes that can transduce subtle differences in the physicochemical properties of molecules in biofluids. Employing this innovative molecular perception approach has the potential to substantially improve diagnostic capabilities over current standards. Improved detection of early-recurrent and early-stage ovarian cancer would, therefore, markedly increase survival rates. Successful completion of this project will result in the development of optimized machine learning screening strategy for early-recurrent and early-stage ovarian cancer, potentially resulting in a clinically applicable diagnostic screening tool for early-stage ovarian cancer.
Program
Doctoral Award: Doctoral Foreign Study Award (DFSA)
Location
New York, United States of America
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
495513
Name
Goerzen Dana A
Region
New York
Country
United States of America
Orgtype
Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Developing a Molecular Perception-Based Platform for the Early Detection of Ovarian Cancer
Programtype2
Studentship Programs
Orgnameinp2
Direct Payment
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Award: Doctoral Foreign Study Award (DFSA)
Keyworddelim
Biomarker Discovery; Cancer Diagnostics; Carbon Nanotubes; Machine Learning; Mass Spectrometry,; Near-Infrared Fluorescence; Ovarian Cancer; Proteomics
Abstract
Ovarian cancer is the most common gynecological malignancy in Canada, killing over 2 400 women annually. Despite advances in the understanding and treatment of ovarian cancer, survival is poor, especially if diagnosed at a late stage and early-stage detection is rare. This proposal investigates a strategy to improve the diagnosis and screening of ovarian cancer and to identify novel disease biomarkers via a liquid biopsy artificial intelligence-nanosensor prognosis prediction platform. We believe that the differentiation of disease from normal biofluids may be achieved by the detection of a "disease fingerprint" through the acquisition of large data sets of molecular binding interactions to a diverse set of moderately selective sensors, which are used to train machine learning algorithms. We are developing this capability using sensor arrays of chemically modified carbon nanotubes that can transduce subtle differences in the physicochemical properties of molecules in biofluids. Employing this innovative molecular perception approach has the potential to substantially improve diagnostic capabilities over current standards. Improved detection of early-recurrent and early-stage ovarian cancer would, therefore, markedly increase survival rates. Successful completion of this project will result in the development of optimized machine learning screening strategy for early-recurrent and early-stage ovarian cancer, potentially resulting in a clinically applicable diagnostic screening tool for early-stage ovarian cancer.
Competitiondate
202310
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Goerzen, Dana A
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~
Direct Payment - $105,000 Grant (2023-24) | Canada Spends